Glenmark Pharmaceuticals Ltd. (GLENMARK): Glenmark Pharmaceuticals Share Price Falls 3.52% as Large Cap Stock Clears Threshold

Glenmark Pharmaceuticals Ltd. fell to Rs 2,226.95, down 3.52% today, taking its market capitalisation to Rs 65,645.46 crore and placing it among notable large-cap decliners.

Glenmark Pharmaceuticals Share Price came under pressure on 19 August 2026, with the stock trading at Rs 2,226.95, down 3.52% from the previous close of Rs 2,308.20. That move reduced the company’s market capitalisation to Rs 65,645.46 crore and brought the stock into focus in today’s Stock Market Today and Share Market Today screens for notable downside price action. For investors tracking Glenmark Pharmaceuticals Share Price Today, the supplied data confirms a sharp same-day decline rather than a broader long-term event.

The day’s move is relevant because the stock falls into the Large Cap category and still cleared its qualifying downside threshold for this event screen. In simple terms, this was not just routine intraday volatility. Glenmark Pharmaceuticals Stock News is therefore being watched because the price fall was large enough, within its own market-cap bucket, to stand out among market movers and top losers today.

The verified data establishes what happened in price and volume, but it does not establish a company-specific catalyst behind the decline. That matters for anyone reading Glenmark Pharmaceuticals News Today: the market is clearly repricing the stock lower in the session, yet the dataset supports only the fact of the move, not a confirmed reason.

Within the first half of trade, the stock opened near its previous close, slipped from the day’s high, and moved close to the session low. Alongside the price action, volume was concentrated far more on NSE than BSE, giving traders and long-term trackers a useful lens on participation. Univest views Glenmark Pharmaceuticals Share Price as an event-led story today, but one that still needs to be assessed through market-cap context, sector data, peer positioning and the broader Healthcare landscape.

Glenmark Pharmaceuticals Ltd. (GLENMARK) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,226.95
Previous Close	Rs 2,308.2
Today's Change	Rs -81.25 (-3.52%)
Day Open	Rs 2,300.95
Day High	Rs 2,310
Day Low	Rs 2,224.35
Current Volume (BSE)	12,264
BSE Traded Volume	12,264
NSE Traded Volume	3,87,875
Combined NSE + BSE Volume	4,00,139
Turnover	Rs 2.73 crore
Market Capitalisation	Rs 65,645.46 crore
Market Cap Category	Large Cap

Glenmark Pharmaceuticals Ltd. (GLENMARK) traded at Rs 2,226.95. versus the previous close of Rs 2,308.2, a fall of 3.52%. The stock opened at Rs 2,300.95, reached Rs 2,310, touched Rs 2,224.35. Reported volume was 12,264.

Glenmark Pharmaceuticals Ltd. (GLENMARK) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 65,645.46 crore

Glenmark Pharmaceuticals Share Price is drawing investor attention today mainly because the decline is happening in a company with a market capitalisation of Rs 65,645.46 crore, which places it far above the typical company size shown in the supplied Healthcare benchmark set. Even without a full set of company financial ratios in the dataset, the current market value still offers important fundamental context.

At Rs 65,645.46 crore, Glenmark Pharmaceuticals Market Cap is substantially larger than the benchmark median market capitalisation of Rs 134.22 crore and the benchmark average of Rs 465.93 crore across 196 companies in the same sector sample. It also sits above the benchmark maximum of Rs 2,752.33 crore listed in that supplied universe. That gap is notable because it shows Glenmark is being assessed by the market as a much larger listed healthcare business than the companies used in the comparison set.

From a financial-analysis perspective, this means Glenmark Pharmaceuticals Share Price is not moving inside the valuation band of a small or mid-sized healthcare name. Instead, the stock is reacting as a large listed company whose absolute market value remains significant despite the day’s fall. In practical terms, an Rs 81.25 decline in the stock price translates into meaningful market-value movement because the base capitalisation is already large.

The supplied data does not confirm a company-specific trigger, earnings update or financial-results event behind the move. So, for readers looking for Glenmark Pharmaceuticals Financial Results, Glenmark Pharmaceuticals Earnings or Glenmark Pharmaceuticals Fundamental Analysis, the clean conclusion from today’s verified numbers is narrower: the stock has recorded a notable price fall, and that move matters because it comes in a high-market-cap healthcare company rather than a thinly traded micro-cap name.

Univest therefore reads today’s action less as an isolated print and more as a material market update in a heavyweight stock. That makes it useful to shift from absolute size to relative context by examining sector benchmarks and the peer group.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Benchmark Median P/E	26.65x
Benchmark Average P/E	59.25x
Benchmark P/E Range	2.7x to 1,635.98x
Benchmark Median P/B	1.92x
Benchmark Median ROE	11.12%
Benchmark Median ROCE	13.35%
Company Market Capitalisation	Rs 65,645.46 crore
Benchmark Median Market Cap	Rs 134.22 crore

Glenmark Pharmaceuticals Ltd. (GLENMARK) is classified under sector: Healthcare.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Glenmark Pharmaceuticals Share Price is moving lower within the broader Healthcare sector, and the benchmark data helps show how unusual the company’s size is relative to the supplied sector sample. The same-sector comparison includes 196 companies, offering a broad reference point for valuation, profitability and scale.

The benchmark scope is explicitly the same sector, with 196 companies forming the comparison universe. Within that set, the median market capitalisation is Rs 134.22 crore and the average is Rs 465.93 crore, while the minimum is Rs 3.67 crore and the maximum is Rs 2,752.33 crore. Against that backdrop, Glenmark Pharmaceuticals Market Cap of Rs 65,645.46 crore stands out dramatically. This does not by itself say whether the stock is expensive or inexpensive, but it does show that Glenmark sits in a very different size bracket from most names in the supplied Healthcare basket.

The benchmark also provides valuation and return data for the sector. Across 156 companies, the median P/E is 26.65 and the average P/E is 59.25, with a range from 2.70 to 1,635.98. Across 194 companies, the median P/B is 1.92 and the average is 2.60, with values ranging from -12.12 to 16.81. Profitability benchmarks show median ROE of 11.12 and average ROE of 15.66 across 195 companies, while median ROCE is 13.35 and average ROCE is 17.87 across the same company count.

For Univest readers, that makes Glenmark Pharmaceuticals Share Price News especially relevant. A 3.52% fall in a large-cap healthcare company should not be read the same way as a similar percentage move in a company near the sector median size. The market-cap contrast alone justifies investor attention, which is why peer comparison is the next logical step.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,752.33	0	0.69	-2.89	-0.26
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,724.51	51.17	2.03	-0.78	8.31
Beta Drugs Ltd.	BETA	2,697.08	62.93	9.96	18.65	22.17
Hikal Ltd.	HIKAL	2,622.61	0	2.25	15.22	16.15
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,583.65	33.9	6.99	36.29	42.4

Glenmark Pharmaceuticals Ltd. (GLENMARK) has a market capitalisation of Rs 65,645.46 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Glenmark Pharmaceuticals Share Price can also be better understood by placing the company beside the supplied listed peers from Healthcare and related pharmaceutical businesses. The peer set includes names such as Dishman Carbogen Amcis, Ind-Swift Laboratories, Beta Drugs, Hikal, Dr Agarwals Eye Hospital, Panacea Biotec, Solara Active Pharma Sciences, Sai Parenteral's, Fredun Pharmaceuticals and Venus Remedies.

The most immediate comparison point is scale. Glenmark Pharmaceuticals Ltd. has a market capitalisation of Rs 65,645.46 crore, while the largest peer in the supplied table, Dishman Carbogen Amcis Ltd., stands at Rs 2,752.33 crore. Ind-Swift Laboratories is at Rs 2,724.51 crore, Beta Drugs at Rs 2,697.08 crore, Hikal at Rs 2,622.61 crore and Dr Agarwals Eye Hospital at Rs 2,583.65 crore. This means Glenmark is operating at many multiples of the peer market-cap figures included here.

Profitability and valuation within the peer set are varied. Beta Drugs shows ROE of 18.65 and ROCE of 22.17 with a P/E of 62.93 and P/B of 9.96. Dr Agarwals Eye Hospital shows stronger return ratios still, with ROE of 36.29 and ROCE of 42.40, alongside a P/E of 33.90 and P/B of 6.99. Hikal reports P/B of 2.25 with ROE of 15.22 and ROCE of 16.15. Solara Active Pharma Sciences has P/B of 2.07, ROE of 17.23 and ROCE of 15.34. Venus Remedies trades at a lower supplied P/E of 20.81 and P/B of 3.52, with ROE of 9.85 and ROCE of 7.89.

At the weaker end of the return spectrum, Dishman Carbogen Amcis shows ROE of -2.89 and ROCE of -0.26, while Ind-Swift Laboratories shows ROE of -0.78 and ROCE of 8.31. Panacea Biotec has ROE of 0 and ROCE of 5.36. This spread highlights how mixed the Healthcare and pharmaceuticals space can be, with some peers generating strong returns and others still reflecting operational strain.

For Glenmark Pharmaceuticals Share Price Today, the peer lesson is straightforward. The company’s market value is far larger than all supplied peers, so a day’s decline in this stock carries a different market-weight significance. Univest sees that as one reason Glenmark Pharmaceuticals Share News is likely to remain on trader and investor watchlists through the session.

Why Investors Are Watching Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Share Price is under active watch because the stock has delivered a verified 3.52% same-day decline, enough to qualify on a market-cap-adjusted downside screen. The move is notable not only for its size, but also because it comes in a large-cap healthcare company with a market capitalisation of Rs 65,645.46 crore. For market participants tracking Stocks in News, Top Losers Today and Stocks Falling Today, that combination of scale and price action makes the stock relevant.

• Verified price action: The stock fell Rs 81.25 from Rs 2,308.20 to Rs 2,226.95.
• Intraday structure: It opened at Rs 2,300.95, hit Rs 2,310.00, and slipped to Rs 2,224.35.
• Volume participation: Total volume was 4,00,139 shares, with 3,87,875 shares on NSE and 12,264 on BSE.
• Market-cap context: Glenmark remains a Large Cap company with market capitalisation of Rs 65,645.46 crore.
• Sector positioning: Its market value is far above the supplied Healthcare benchmark median and average.

What investors should monitor next is whether Glenmark Pharmaceuticals Share Price stabilises away from the day low or continues to trade near session lows as Market News develops. They may also watch whether turnover builds beyond the reported Rs 2.73 crore on the stated exchange and whether the stock continues to feature among market movers. Univest would frame this as a price-action story first, with sector and peer context helping explain why the decline is being noticed so closely.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd. is being analysed here within the Healthcare sector context provided in the dataset. The peer and sector universe around it is heavily represented by Pharmaceuticals & Drugs companies, alongside selected Hospital & Healthcare Services names, which places Glenmark Pharmaceuticals Share Price firmly within a market segment that investors often track for valuation spreads, profitability differences and stock-specific price action.

The supplied comparison set shows Glenmark being viewed alongside pharmaceutical businesses such as Dishman Carbogen Amcis, Ind-Swift Laboratories, Beta Drugs, Hikal, Panacea Biotec, Solara Active Pharma Sciences, Sai Parenteral's, Fredun Pharmaceuticals and Venus Remedies. That peer grouping makes Glenmark Pharmaceuticals Stock News relevant for investors who compare listed healthcare names not just on short-term movement, but also on scale and sector standing.

From a market-position perspective, the most important verified takeaway is that Glenmark is much larger by market capitalisation than the supplied listed peers and also far above the broader Healthcare benchmark sample. That does not replace detailed company financials or business-segment disclosure, but it does show that Glenmark Pharmaceuticals Ltd. occupies a prominent place in the quoted Healthcare universe represented here.

For readers following Glenmark Pharmaceuticals NSE, Glenmark Pharmaceuticals BSE and Glenmark Pharmaceuticals Latest News, today’s move therefore sits at the intersection of stock-specific price action and broader healthcare-sector monitoring.

Track Glenmark Pharmaceuticals Share Price on Univest

Use Glenmark Pharmaceuticals Ltd. (GLENMARK) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Investors who want to follow Glenmark Pharmaceuticals Share Price more closely can use Univest to track live share price movement, market-cap changes and stock-specific updates through the trading session. Glenmark Pharmaceuticals Share Price Today is especially relevant when a stock appears on downside event screens, because users often want one place to review intraday price action alongside broader market context.

On Univest, users can track Glenmark Pharmaceuticals Share Price Live, compare the stock with healthcare peers, review market-cap positioning, monitor 52-week levels when available, and follow changes in momentum screens across the Indian Stock Market. They can also use Univest for structured stock updates, sector snapshots and company-level market insights without relying on fragmented sources. For event-led sessions like this one, that helps place a sharp intraday decline in a cleaner analytical framework.

Frequently Asked Questions

Why is Glenmark Pharmaceuticals Share Price falling today?

Ans. Glenmark Pharmaceuticals Share Price is down 3.52% today, falling from the previous close of Rs 2,308.20 to Rs 2,226.95. The supplied data confirms the price event and trading activity, but it does not establish a company-specific catalyst.

What is Glenmark Pharmaceuticals Share Price Today?

Ans. Glenmark Pharmaceuticals Share Price Today is Rs 2,226.95 at the time captured in the dataset. The stock was down Rs 81.25 on the day, after opening at Rs 2,300.95 and moving close to its intraday low.

How much did Glenmark Pharmaceuticals Ltd. fall compared with the previous close?

Ans. Glenmark Pharmaceuticals Ltd. declined by Rs 81.25 compared with its previous close of Rs 2,308.20. In percentage terms, Glenmark Pharmaceuticals Share Price fell 3.52%, making it a notable large-cap decliner in today’s market update.

What were the day high and day low for Glenmark Pharmaceuticals shares?

Ans. The stock touched a day high of Rs 2,310.00 and a day low of Rs 2,224.35. With the current price at Rs 2,226.95, Glenmark Pharmaceuticals Share Price was trading very close to the session low.

Why is this decline considered significant for Glenmark Pharmaceuticals Share Price?

Ans. The decline is significant because Glenmark is classified as a Large Cap stock and still cleared the exact 3% qualifying downside threshold. Its 3.52% fall therefore exceeded the event bar for that market-cap category.

What was the traded volume in Glenmark Pharmaceuticals shares today?

Ans. Total traded volume stood at 4,00,139 shares in the supplied data. Of this, NSE contributed 3,87,875 shares and BSE contributed 12,264 shares, showing that most activity in Glenmark Pharmaceuticals Share Price was concentrated on NSE.

What was the turnover reported for Glenmark Pharmaceuticals today?

Ans. The reported turnover was Rs 2.73 crore on the stated exchange data in the workflow. Alongside the 3.52% decline, that turnover figure helps frame Glenmark Pharmaceuticals Share Price as an active market event today.

What is the market capitalisation of Glenmark Pharmaceuticals Ltd.?

Ans. Glenmark Pharmaceuticals Ltd. had a market capitalisation of Rs 65,645.46 crore in the supplied dataset. That makes Glenmark Pharmaceuticals Share Price relevant not just as a falling stock, but as a move in a large listed healthcare company.

How does Glenmark’s market cap compare with the Healthcare benchmark sample?

Ans. Glenmark’s market capitalisation of Rs 65,645.46 crore is far above the benchmark median of Rs 134.22 crore and average of Rs 465.93 crore across 196 Healthcare companies. It also exceeds the benchmark maximum of Rs 2,752.33 crore.

Which peers are commonly compared with Glenmark Pharmaceuticals in this analysis?

Ans. The supplied peer set includes Dishman Carbogen Amcis, Ind-Swift Laboratories, Beta Drugs, Hikal, Dr Agarwals Eye Hospital, Panacea Biotec, Solara Active Pharma Sciences, Sai Parenteral's, Fredun Pharmaceuticals and Venus Remedies within Healthcare.